ALX Oncology Holdings Inc
(NAS:ALXO)
$
8.43
-0.09 (-1.06%)
Market Cap: 439.20 Mil
Enterprise Value: 297.20 Mil
PE Ratio: 0
PB Ratio: 2.61
GF Score: 34/100 - ALX Oncology Holdings Inc at JPMorgan Healthcare Conference TranscriptJan 09, 2024
- ALX Oncology Holdings Inc at UBS BioPharma Conference TranscriptNov 08, 2023
- ALX Oncology Holdings Inc at Cantor Fitzgerald Global Healthcare Conference TranscriptSep 26, 2023
- ALX Oncology Holdings Inc at JPMorgan Healthcare Conference TranscriptJan 10, 2023
- ALX Oncology Holdings Inc Discuss The Initial AML Data From ASPEN-05 - Conference Call TranscriptDec 13, 2022
- ALX Oncology Holdings Inc at Credit Suisse Healthcare Conference TranscriptNov 09, 2022
- ALX Oncology Holdings Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 11, 2022
- ALX Oncology Holdings Inc SITC 2021 Conference Call TranscriptNov 09, 2021
- ALX Oncology Holdings Inc at Credit Suisse Healthcare Conference (Virtual) TranscriptNov 08, 2021
- ALX Oncology Holdings Inc to Discuss New Data from ASPEN-01 and the Phase 1b Study of ALX148 Call TranscriptJul 06, 2021
- ALX Oncology Holdings Inc Annual Shareholders Meeting TranscriptJun 10, 2021
- ALX Oncology Holdings Inc at Jefferies Healthcare Conference (Virtual) TranscriptJun 02, 2021
- ALX Oncology Holdings Inc at UBS Global Healthcare Virtual Conference TranscriptMay 24, 2021
- ALX Oncology Holdings Inc at H C Wainwright Global Life Sciences Conference (Virtual) - Pre-Recorded Fireside Chat TranscriptMar 09, 2021
- ALX Oncology Holdings Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 12, 2021
- ALX Oncology Holdings Inc at Jefferies Virtual London Healthcare Conference TranscriptNov 19, 2020
ALX Oncology Holdings Inc at UBS BioPharma Conference Transcript
Nov 08, 2023 / 06:30PM GMT
Release Date Price:
$9.01
(-1.21%)
Colin Nigel Bristow
UBS Investment Bank, Research Division - Analyst
Good afternoon, everyone, and thank you for coming to the UBS Biopharma Conference here in beautiful Miami. I'm Colin Bristow, one of the biotech analysts. It's my pleasure to have ALX Oncology with us here today. On behalf of the company, we have CEO, Jason Lettmann; and President and Chief Scientific Officer, Jaume Pons. So thanks for being with us here today.
Jason W. Lettmann
ALX Oncology Holdings Inc. - CEO & Director
Thanks for having us.
Questions & Answers
Colin Nigel Bristow;Jason W. Lettmann
UBS Investment Bank, Research Division - Analyst;ALX Oncology Holdings
So maybe let's start with a sort of a relatively broad question around the CD47 space. What are your current thoughts about the overall CD47 field? We've seen some sort of reasonable, I'd say, disappointing data from competitors. So what is your current thinking and excitement? And how do you see evorpacept just being differentiated?
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)